Bleeding risk of glycoprotein (GP) IIB IIIA inhibitors or thienopyridines with fondaparinux vs enoxaparin in acute coronary syndromes: Insights from the oasis 5 trial Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

publication date

  • October 1, 2007